This is a non-interventional, multicenter study to evaluate efficacy and safety of
intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for
first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC)
in daily routine.